Florian Szymczak,Maria Inês Alvelos,Sandra Marín-Cañas,Ângela Castela,Stéphane Demine,Maikel Luis Colli,Anne Op de Beeck,Sofia Thomaidou,Lorella Marselli,Arnaud Zaldumbide,Piero Marchetti,Décio L. Eizirik

Abstract:IFNα is a key regulator of the dialogue between pancreatic β cells and the immune system in early type 1 diabetes (T1D). IFNα up-regulates HLA class I expression in human β cells, fostering autoantigen presentation to the immune system. We observed by bulk and single-cell RNA sequencing that exposure of human induced pluripotent-derived islet-like cells to IFNα induces expression of HLA class I and of other genes involved in antigen presentation, including the transcriptional activator NLRC5. We next evaluated the global role of NLRC5 in human insulin-producing EndoC-βH1 and human islet cells by RNA sequencing and targeted gene/protein determination. NLRC5 regulates expression of HLA class I, antigen presentation–related genes, and chemokines. NLRC5 also mediates the effects of IFNα on alternative splicing, a generator of β cell neoantigens, suggesting that it is a central player of the effects of IFNα on β cells that contribute to trigger and amplify autoimmunity in T1D.

Transcription and splicing regulation by NLRC5 shape the interferon response in human pancreatic β cells